Effect of sorbinil on blood-retinal barrier in early diabetic retinopathy.
To study the effect of sorbinil on the alteration of the blood-retinal barrier, 32 adult-onset, non-insulin-dependent diabetic patients with minimal or no retinopathy were randomly assigned to receive either oral sorbinil (250 mg once a day) or a placebo for 6 mo. All patients underwent fundus photography, fluorescein angiography, and vitreous fluorophotometry before treatment and at 3 and 6 mo after treatment. Vitreous fluorophotometry data showed that the alteration of the blood-retinal barrier increased significantly less in the sorbinil-treated group compared with the placebo group during the 6-mo study period. Side effects were limited to hypersensitivity reactions, with skin rash and fever, in only 2 of the 16 patients who received the drug. These hypersensitivity reactions disappeared with discontinuation of the medication. Aldose-reductase inhibition may play an important role in stabilization of the blood-retinal barrier in early diabetic retinopathy.
D000328:Adult; D002986:Clinical Trials as Topic; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D005260:Female; D019793:Fluorescein; D005451:Fluorescein Angiography; D005452:Fluoresceins / Q000097:blood; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D048289:Imidazolidines; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012160:Retina / Q000473:pathology; D012171:Retinal Vessels / Q000473:pathology; D014822:Vitreous Body / Q000473:pathology
D005452:Fluoresceins; D007093:Imidazoles; D048289:Imidazolidines; C026411:sorbinil; D019793:Fluorescein